RE:RE:RE:RE:ONCY presents 2 posters at ASCO 2024May 24, 2024 - Regeneron Pharmaceuticals released underwhelming bispecific Phase I/II data on its ongoing bispecific antibody study in patients with advanced solid tumors. REGN7075 is a costimulatory bispecific antibody that is intended to work by bridging CD28-positive T cells with tumor cells expressing the EGFR protein. This mechanism of action was thought to allow REGN7075 to restore the immune sensitivity of tumor cells and activate the anti-cancer functions of T-cells. The effect was underwhelming.
The resulting overall response rate was 20%.
https://www.biospace.com/article/asco24-regeneron-s-bispecific-antibody-falls-flat-in-early-study-with-just-one-complete-response/